α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis

2017 ◽  
Vol 86 (2) ◽  
pp. e11-e12
Author(s):  
Yosuke Kanno ◽  
En Shu ◽  
Hiroyuki Kanoh ◽  
Ayaka Matsuda ◽  
Mariko Seishima
Keyword(s):  
Systemic Sclerosis ◽  
Vegf Signaling ◽  
Vascular Alteration

scholarly journals The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis

2019 ◽  
Vol 15 (2) ◽  
pp. 99-109 ◽  
Author(s):  
Victoria A. Flower ◽  
Shaney L. Barratt ◽  
Stephen Ward ◽  
John D. Pauling
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Systemic Sclerosis ◽  
Growth Factor ◽  
Current Treatment ◽  
Vascular Endothelial ◽  
Vegf Signaling ◽  
Splice Isoform ◽  
Isoform Expression ◽  
Endothelial Growth Factor

The pathological hallmarks of Systemic Sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of Vascular Endothelial Growth Factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential Vascular Endothelial Growth Factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.

Screen for PAH in Systemic Sclerosis Patients

2008 ◽  
Vol 41 (18) ◽  
pp. 21
Author(s):  
SHARON WORCESTER
Keyword(s):  
Systemic Sclerosis
Sign in / Sign up

Export Citation Format

Share Document